JP2015524823A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524823A5
JP2015524823A5 JP2015525617A JP2015525617A JP2015524823A5 JP 2015524823 A5 JP2015524823 A5 JP 2015524823A5 JP 2015525617 A JP2015525617 A JP 2015525617A JP 2015525617 A JP2015525617 A JP 2015525617A JP 2015524823 A5 JP2015524823 A5 JP 2015524823A5
Authority
JP
Japan
Prior art keywords
composition according
antithrombin
recombinant antithrombin
administered
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015525617A
Other languages
English (en)
Japanese (ja)
Other versions
JP6389172B2 (ja
JP2015524823A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/053365 external-priority patent/WO2014022748A1/en
Publication of JP2015524823A publication Critical patent/JP2015524823A/ja
Publication of JP2015524823A5 publication Critical patent/JP2015524823A5/ja
Application granted granted Critical
Publication of JP6389172B2 publication Critical patent/JP6389172B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015525617A 2012-08-03 2013-08-02 体外式膜型人工肺におけるアンチトロンビンの使用 Expired - Fee Related JP6389172B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679345P 2012-08-03 2012-08-03
US61/679,345 2012-08-03
PCT/US2013/053365 WO2014022748A1 (en) 2012-08-03 2013-08-02 The use of antithrombin in extracorporeal membrane oxygenation

Publications (3)

Publication Number Publication Date
JP2015524823A JP2015524823A (ja) 2015-08-27
JP2015524823A5 true JP2015524823A5 (cg-RX-API-DMAC7.html) 2016-09-23
JP6389172B2 JP6389172B2 (ja) 2018-09-12

Family

ID=50028554

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015525617A Expired - Fee Related JP6389172B2 (ja) 2012-08-03 2013-08-02 体外式膜型人工肺におけるアンチトロンビンの使用

Country Status (13)

Country Link
US (1) US9511087B2 (cg-RX-API-DMAC7.html)
EP (1) EP2879697A4 (cg-RX-API-DMAC7.html)
JP (1) JP6389172B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150039201A (cg-RX-API-DMAC7.html)
CN (1) CN104884080A (cg-RX-API-DMAC7.html)
AR (1) AR091977A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013296240B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015002321A2 (cg-RX-API-DMAC7.html)
CA (1) CA2879763C (cg-RX-API-DMAC7.html)
IL (1) IL236776A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015001508A (cg-RX-API-DMAC7.html)
TW (1) TW201425332A (cg-RX-API-DMAC7.html)
WO (1) WO2014022748A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116585504A (zh) 2010-12-30 2023-08-15 法国化学与生物科技实验室 作为病原体灭活剂的二元醇
TW201425332A (zh) 2012-08-03 2014-07-01 Revo Biolog Inc 抗凝血酶用於體外膜氧合之用途
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
TW201509432A (zh) 2013-07-05 2015-03-16 Lab Francais Du Fractionnement 親和層析基質
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3388140A1 (en) * 2017-04-10 2018-10-17 Gambro Lundia AB Extracorporeal blood circuit

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US5801063A (en) 1995-05-09 1998-09-01 Grandics; Peter Device and process for the biospecific removal of heparin
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
JP2001512976A (ja) 1997-02-25 2001-08-28 ジェンザイム・トランスジェニックス・コーポレーション トランスジェニックにより産生された非分泌性タンパク質
US20060264357A1 (en) * 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
DE10159556A1 (de) 2001-12-05 2003-06-12 Aventis Behring Gmbh Intellect Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
JP2007503838A (ja) 2003-09-05 2007-03-01 ジーティーシー バイオセラピューティクス, インコーポレイティド トランスジェニック動物の乳汁中での融合タンパク質の産生方法
CA2479968A1 (en) 2004-09-01 2006-03-01 Keith R. Walley Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome
US20060292213A1 (en) 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
EP1913155A4 (en) 2005-06-23 2009-08-12 Univ British Columbia COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION RELATING TO THE RESULTS AND RESPONSE OF A SUBJECT TO THERAPY
WO2007014244A2 (en) 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
KR20080068089A (ko) 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
US20070292407A1 (en) 2005-12-12 2007-12-20 The Board Of Trustees Operating Michigan State University Methods of treatment for meconium aspiration syndrome
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
US8173860B2 (en) 2006-04-21 2012-05-08 Gtc Biotherapeutics, Inc. Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20110082083A1 (en) 2009-04-10 2011-04-07 Gtc Biotherapeutics, Inc. Formulations of liquid stable antithrombin
US8551096B2 (en) 2009-05-13 2013-10-08 Boston Scientific Scimed, Inc. Directional delivery of energy and bioactives
JP6178311B2 (ja) 2011-07-07 2017-08-09 エルエフビー ユーエスエー インコーポレイテッドLfb Usa, Inc. タンパク質を安定化する製剤
TW201400499A (zh) 2012-03-12 2014-01-01 Revo Biolog Inc 抗凝血酶用於治療妊娠毒血症之用途
TW201425332A (zh) 2012-08-03 2014-07-01 Revo Biolog Inc 抗凝血酶用於體外膜氧合之用途

Similar Documents

Publication Publication Date Title
JP2015524823A5 (cg-RX-API-DMAC7.html)
JP2014530874A5 (cg-RX-API-DMAC7.html)
NZ631155A (en) Combination of two antivirals for treating hepatitis c
MX384836B (es) Agentes antivirales contra la hepatitis b
FI3494972T3 (fi) Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon
BR112012033715A2 (pt) inibidores de quinase de regulação de sinal de apoptose.
JP2013509429A5 (cg-RX-API-DMAC7.html)
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
HRP20171898T1 (hr) Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika
JP2017501154A5 (cg-RX-API-DMAC7.html)
FI3978074T3 (fi) Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi
ME02405B (me) Spojevi pirazola као inhibitori sglt1
JP2015516419A5 (cg-RX-API-DMAC7.html)
FI3630164T3 (fi) Dulaglutidi kroonisen munuaissairauden hoitoon
HK1255481A1 (zh) 用於治疗hcv的方法
FI3648788T3 (fi) Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
CN102488697A (zh) 一种寡聚甘露糖醛酸在制备抗甲型h1n1流感病毒药物中的应用
Hogan et al. α1-Antitrypsin: key player or bystander in acute respiratory distress syndrome?
JP2017508455A5 (cg-RX-API-DMAC7.html)
JP2010538054A5 (cg-RX-API-DMAC7.html)
WO2012040164A3 (en) Tlr5 ligands, therapeutic methods, and compositions related thereto
JP2016510040A5 (cg-RX-API-DMAC7.html)
NZ708511A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
HRP20241358T1 (hr) Liječenje hipotenzije sa sepsom ili septičkim šokom